Lupin Ltd.'s consolidated net profit rose 74% in the second quarter of the financial year, beating analysts' estimates.
The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the year-ago period, according to an exchange filing on Thursday. Analysts tracked by Bloomberg had estimated a profit of Rs 742 crore.
Lupin Q2 FY25 Earnings Highlights (Consolidated, YoY)
Revenue up 13% to Rs 5,672.7 crore versus Rs 5,038.6 crore (Bloomberg estimate: Rs 5,560 crore).
Ebitda up 41.7% to Rs 1,308 crore versus Rs 923 crore (Bloomberg estimates Rs 1,203 crore).
Margin expands to 23.1% versus 18.3% (Estimate: 21.6%).
Net profit up 74% to Rs 852.6 crore versus Rs 489.7 crore (Estimate: Rs 742 crore).
North America
Lupin's North America sales reached Rs 1,971 crore, a 5.6% increase and accounting for 36% of the company’s global sales. US sales rose to Rs 1,834 crore from Rs 1,776 crore in the year-ago period.
Lupin received 10 abbreviated-new-drug-application approvals from the FDA and launched two new products, bringing its US generics portfolio to 162 products.
India
Lupin's India formulation sales reached Rs 2,010 crore, marking an 19% increase and representing 37% of Lupin's global sales. During the first half of the fiscal, the company launched five brands across diabetes, neuro/CNS, gastrointestinal, cardiac and gynae therapies.
Sales in growth markets (Asia–Pacific and Latin America) reached Rs 490 crore, a 12% increase and contributing 9% to Lupin's global sales. Sales in Europe, the Middle East and Africa rose 20% to Rs 569 crore, accounting for 10% of the company's global sales.
Global active-pharmaceutical-ingredient sales rose 9.7% to Rs 294 crore, contributing 5% to the company's global sales.
Shares of Lupin closed 2.52% lower at Rs 2,110.55 apiece on the NSE, compared to a 1.16% decline in the benchmark Nifty 50.
RECOMMENDED FOR YOU
Whirlpool Block Deal: Promoter Set To Sell Shares Worth Nearly Rs 1,000 Crore
IDBI Bank Stake Sale: Kotak Mahindra Likely Frontrunner; Fairfax, Oaktree Capital Also In Race
Lupin, Fortis Among Axis Securities Top 'Buy' In Pharma, Healthcare Space; Q2 Review — Details Inside
Lupin Shares Climb 2% Led By Strong Q2 Revenue, Operating Income
POPULAR